Manufacturers (1164 Offers)
Product Information
Dragon PharmaCompound Details
Active Substance Gonadorelin (GnRH) Lyophilized gonadotropin-releasing hormone analogue
10 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life Limited human data · short-acting
Detection Limited data · Up to several weeks
Primary Mechanism GnRH Receptor Agonism (Pulsatile)
HPTA / Gonadotropin Support High (limited human data)
Product Information
Dragon PharmaCompound Details
Active Substance B7-33 Lyophilized single-chain relaxin-2 analogue (RXFP1 agonist)
10 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life Approximately 6 Minutes (in vitro serum)
Detection Limited data · Up to several weeks
Primary Mechanism RXFP1 Agonism (Relaxin Receptor)
Anti-Fibrotic / Tissue Remodeling Impact High (preclinical)
Product Information
Dragon PharmaCompound Details
Active Substance Bronchogen Lyophilized bioregulatory peptide (Khavinson, lung-targeted)
20 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life Limited human data · short-acting
Detection Limited data · Up to several weeks
Primary Mechanism Proposed Bronchial Gene-Expression Modulation
Cellular / Regenerative Impact Low (limited human data)
Product Information
Dragon PharmaCompound Details
Active Substance Cardiogen (AEDR) Lyophilized bioregulatory tetrapeptide (Khavinson, cardiac-targeted)
20 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life Limited human data · short-acting
Detection Limited data · Up to several weeks
Primary Mechanism Proposed Cardiac Gene-Expression Modulation
Cellular / Regenerative Impact Low (limited human data)
Product Information
Dragon PharmaCompound Details
Active Substance FOXO4-DRI Lyophilized senolytic peptide (D-retro-inverso FOXO4/p53 inhibitor)
10 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life No published human PK data
Detection Limited data
Primary Mechanism FOXO4–p53 Disruption / Senolytic Apoptosis
Senolytic / Cellular Impact Low (no human data)
Product Information
Dragon PharmaCompound Details
Active Substance GHK-Cu (Copper Peptide) Lyophilized copper-binding tripeptide (basic form)
10 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life Limited human data · short-acting
Detection Limited data · Up to several weeks
Primary Mechanism Copper-Dependent Collagen & Tissue Remodeling
Tissue Repair / Healing High (preclinical)
Product Information
Dragon PharmaCompound Details
Active Substance PNC-27 Lyophilized experimental anti-cancer peptide (p53-derived / HDM-2 targeting)
10 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life No published human PK data
Detection Limited data · S0-prohibited (non-approved substance)
Primary Mechanism Membrane HDM-2 Binding / Pore Formation
Anti-Cancer / Cellular Impact No Human Data